KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Rad Laboratories (BIO) FCF Margin (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed FCF Margin for 17 consecutive years, with 6.61% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin fell 1879.0% to 6.61% in Q4 2025 year-over-year; TTM through Dec 2025 was 6.1%, a 1738.0% decrease, with the full-year FY2025 number at 6.1%, down 1738.0% from a year prior.
  • FCF Margin was 6.61% for Q4 2025 at Bio-Rad Laboratories, down from 4.85% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 26.2% in Q3 2021 to a low of 7.01% in Q2 2025.
  • A 5-year average of 4.55% and a median of 5.27% in 2023 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: soared 2929bps in 2021, then crashed -3025bps in 2022.
  • Bio-Rad Laboratories' FCF Margin stood at 15.65% in 2021, then crashed by -61bps to 6.13% in 2022, then decreased by -7bps to 5.69% in 2023, then surged by 114bps to 12.18% in 2024, then crashed by -154bps to 6.61% in 2025.
  • Per Business Quant, the three most recent readings for BIO's FCF Margin are 6.61% (Q4 2025), 4.85% (Q3 2025), and 7.01% (Q2 2025).